Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial

Background: The aim was to assess the safety and tolerability of the insulin aspart biosimilar/follow-on product SAR341402 (100 U/mL solution; SAR-Asp) and originator insulin aspart (100 U/mL; NN-Asp; NovoLog(®)) self-administered through an insulin pump. Materials and Methods: This randomized, open...

Descripción completa

Detalles Bibliográficos
Autores principales: Thrasher, James, Polsky, Sarit, Hovsepian, Lionel, Nowotny, Irene, Pierre, Suzanne, Bois De Fer, Béatrice, Bhargava, Anuj, Mukherjee, Bhaswati, Garg, Satish K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478191/
https://www.ncbi.nlm.nih.gov/pubmed/31833801
http://dx.doi.org/10.1089/dia.2019.0446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478191/
https://www.ncbi.nlm.nih.gov/pubmed/31833801
http://dx.doi.org/10.1089/dia.2019.0446

Ejemplares similares